Search
Close this search box.
Follow us

Product

Related

Products

RUXOLITINIB PHOSPHATE

RUXOLITINIB PHOSPHATE

Oncology

Cas No: 1092939-17-7

Mechanism Of Action: Ruxolitinib belongs to the drug class called janus kinase inhibitors (JAK inhibitors). It acts as an inhibitor of the JAK1 and JAK2

OLAPARIB

Oncology

Cas No: 763113-22-0

Mechanism Of Action: Olaparib functions as an inhibitor of poly(ADP-ribose) polymerase, effectively impeding the repair of single-strand DNA breaks. This mechanism leads to synthetic lethality

CRIZOTINIB

Oncology

Cas No: 877399-52-5

Mechanism Of Action: Crizotinib is a tyrosine kinase receptor inhibitor. It inhibits anaplastic lymphoma kinase (ALK), hepatocyte growth factor receptor (HGFR, c-MET), and Recepteur d’Origine

osimertinib Mesylate

Oncology

Cas No: 1421373-66-1

Mechanism Of Action: Osimertinib is an EGFR tyrosine kinase inhibitor that binds to certain mutant forms of EGFR (T790M, L858R, and exon 19 deletion) that

VANDETANIB

Oncology

Cas No: 443913-73-3

Mechanism Of Action: Vandetanib is a selective and potent inhibitor of VEGFR (vascular endothelial growth factor receptor), EGFR (epidermal growth factor receptor) and RET (RE-arranged

Dasatinib Anhydrous

Oncology

Cas No: 302962-49-8

Mechanism Of Action: Dasatinib, at nanomolar concentrations can inhibit the following kinases: BCR-ABL, SRC family (SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFRβ. Based on

Dasatinib Monohydrate

Oncology

Cas No: 863127-77-9

Mechanism Of Action: Dasatinib, at nanomolar concentrations can inhibit the following kinases: BCR-ABL, SRC family (SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFRβ. Based on

Regorafenib Monohydrate

Regorafenib Monohydrate

Oncology

Cas No: 1019206-88-2

Mechanism Of Action: Regorafenib is an inhibitor of multiple membrane-bound and intracellular kinases involved in normal cellular functions and in pathologic processes including, oncogenesis, tumor

Pazopanib HCI

Oncology

Cas No: 635702-64-6

Mechanism Of Action: Pazopanib is a second-generation multi-targeted tyrosine kinase inhibitor against vascular endothelial growth factor receptor-1, -2, and -3, platelet-derived growth factor receptor-alpha, platelet-derived

Lenalidomide Hemihydrate

Lenalidomide hemihydrate

Oncology

Cas No: 847871-99-2

Mechanism Of Action: Exhibits immunomodulatory properties. Activates and increases number of T cells and NK cells Increases number of NKT cells Inhibits pro-inflammatory cytokines (e.g.,